Cheaper eye drug could save millions in AMD treatment costs
NCT ID NCT03577041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment offers the best value. The goal is to help healthcare systems choose the most cost-effective option without compromising patient care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bevacizumab, Ranibizumab, Aflibercept (anti-VEGF drugs given as eye injections)
- What this could lead to
- If successful, this study could show that a cheaper drug (bevacizumab) works just as well as more expensive ones, potentially saving healthcare systems money while maintaining patient outcomes.
- What could go wrong
- This is an observational economic model, not a treatment trial. It won't test new drugs or prove which works best for individual patients. Results may not apply outside France.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can At-Home eye scans personalize wet AMD treatment?
- Can a new eye injection save vision in wet AMD?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments